This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

A new study in Small presents a nanoparticle-based delivery system combining CuET and BIO for treating resistant melanoma, ...

Autoimmune diseases develop when the immune system mistakenly attacks the body’s own tissues by recognizing self-antigens as ...

Vienna, Austria played host to a momentous gathering, welcoming over 15,000 attendees from across five continents for the ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

MIT researchers found a way to measure cell density quickly and accurately -- measuring up to 30,000 cells in a single hour.

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

The WEHI-led study used a novel approach combined with cutting-edge mRNA vaccine technology to increase the formation of a type of T cell which has remarkable self-renewing capacity and can ...

Their study is based on a large-scale meta-analysis of single-cell RNA sequencing and T-cell receptor (TCR) sequencing from cancer patients treated with immunotherapy. This allowed them to examine ...

and efficient alternative to cell line target cells. This helps CAR-T developers accelerate assay validation and lot release, while avoiding the operational burden, variability and chain-of ...